We look for people who turn new technology and customer requirements into qualified, repeatable productive capacity through process translation, scale-up and GMP execution.
The scarcer experience may be not scaling a process, but turning the scaled process into qualified commercial capacity.
Capability · Scale-Up to Qualified Capacity
The capability to move a research or clinical process to larger scale and close quality, regulatory and GMP requirements until it becomes repeatable commercial capacity.
Increasing batch scale is different from redesigning the process, analytical and quality conditions that break at scale and finishing a qualified productive system.
Why now
ST Pharm reports more than 15 years of oligonucleotide manufacturing, technology-transfer and scale-up experience, including GMP oligos for Phase III and commercial uses, while expanding oligonucleotide capacity toward 14.0 mole in 2026.
Core capability
Process Translation
Scale-Up
Qualification
Commercial Manufacturing
Experience that strengthens it
Process Development
Tech Transfer
Manufacturing
QA/QC
Regulatory Affairs
Who to look at first
Process Development / Tech Transfer / Manufacturing depth plus scale-up, qualification and GMP-commercialization experience
What to check in the interview
Ask what failed at scale, which process, analytical or quality conditions changed, and what GMP or commercial state was ultimately reached.
Build internally
Define ownership across Process Development → Tech Transfer → Scale-Up → Quality/Qualification → Manufacturing handoffs.
New RNA modalities repeat the tech-transfer → scale-up → qualification path
Conditions that lower this view
Lower priority if new capacity is used mainly for standardized repeat production, Process/Quality/Manufacturing ownership becomes more separated, or new modalities do not reach commercial manufacturing.
View evidence7
Roles & capabilities
ManufacturingPersistent
Process DevelopmentObserved again
Tech TransferObserved again
Quality AssurancePersistent
Business changes
ST Pharm connects mRNA-LNP technology to a Banwol GMP production platformSource ↗
ST Pharm expands oligonucleotide capacity while preserving tech-transfer and scale-up depthSource ↗
ST Pharm sustains a development-to-commercial cGMP manufacturing modelSource ↗
Talent pattern 2Early watch
Understanding a customer requirement is different from turning it into manufacturable conditions and capacity.
Capability · Customer-to-Capacity Translation
The capability to convert external customer requirements into internal process, quality and regulatory conditions and connect them to manufacturable capacity and delivery.
Communicating with customers is different from translating a requirement into manufacturing specifications, process decisions and quality constraints and closing the loop through GMP production.
Why now
ST Pharm highlights roughly three decades of global client relationships and development-to-commercial cGMP manufacturing, with manufacturing, QC/QA and R&D at Sihwa and Banwol and regulatory-commercial functions in Seoul.
Core capability
Customer Requirement
Technical Translation
Quality/Regulatory Alignment
Manufacturing Delivery
Experience that strengthens it
Tech Transfer
Process Development
Regulatory Affairs
QA/QC
Manufacturing
Who to look at first
Tech Transfer / Process / PM / QA-RA / Manufacturing depth plus customer-to-production translation experience
What to check in the interview
Ask for one case covering the requested condition, manufacturing constraint, alternative design, quality/regulatory impact, customer agreement and final production result.
Build internally
Define translation ownership and acceptance criteria between Client Technical Interface and Process, Quality, Regulatory and Manufacturing.
More customer programs run from development through commercial manufacturing
Customer-specific tech transfer and process-quality-regulatory translation become more complex
New oligonucleotide and RNA programs repeatedly enter the existing manufacturing system
Conditions that lower this view
Lower priority if services become highly standardized, customer interface and manufacturing decisions become fully separated, or short routine production becomes dominant.
View evidence7
Roles & capabilities
ManufacturingPersistent
Process DevelopmentObserved again
Tech TransferObserved again
Quality AssurancePersistent
Business changes
ST Pharm connects mRNA-LNP technology to a Banwol GMP production platformSource ↗
ST Pharm expands oligonucleotide capacity while preserving tech-transfer and scale-up depthSource ↗
ST Pharm sustains a development-to-commercial cGMP manufacturing modelSource ↗
Manufacturing changeST Pharm expands oligonucleotide capacity while preserving tech-transfer and scale-up depth
Oligonucleotide capacity rises across Sihwa and Banwol while technology transfer, scale-up and late-stage/commercial GMP manufacturing remain core service requirements.
Manufacturing changeST Pharm sustains a development-to-commercial cGMP manufacturing model
The company’s long regulatory record and development-to-commercial service model show manufacturing capability being repeatedly fixed into qualified operating standards.
Repeatedly observed: confirmed at several points in time · Observed: confirmed recently
Banseog analysisST Pharm repeatedly turns new modalities and customer programs into qualified productive capacity
CURRENT TALENT MARKET
Then see the talent market moving around it.
Career paths and talent movement linked to this company are still being observed.
Abbreviations on this page
CMC
Chemistry, manufacturing and controls
GMP
Good manufacturing practice
QA
Quality assurance
QC
Quality control
RA
Regulatory affairs
Candidate market analysis for ST Pharm
We analyse the candidate field, adjacent talent markets and hiring sequence for this shift. The detailed candidate field is shared only with the commissioning company.
![Banseog [ biohealth ]](/assets/brand/banseog-biohealth-on-dark.svg?v=20261015){kind=small}